Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at UBS Global Healthcare Conference Transcript

May 24, 2022 / 02:45PM GMT
Release Date Price: $19.35 (-1.07%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Thank you, everyone, for joining us at the UBS Healthcare Conference. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Very happy to be with you all in person. And very happy to have REGENXBIO here with us for a fireside chat for the next 39 minutes and 25 seconds joining us from REGENX is CEO, Ken Mills; and Chief Medical Officer, Steve Pakola. Thank you guys so much for joining us.

Questions & Answers

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Maybe before we get into the juicy questions around what AMD and DME, I'll just -- a broader high-level question. Can you tell us the history a bit about REGENX and the expertise that you guys have as well as IP in the gene therapy front?

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Yes. Thanks, Ellie, to you and the team for hosting us and having this in person. We're happy to be here. And had some great interactions already this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot